IDXG Interpace Biosciences

Interpace Biosciences’ Audit Committee Investigation Finds Complaints Unsubstantiated

Interpace Biosciences’ Audit Committee Investigation Finds Complaints Unsubstantiated
EN
14/10/2020

Underlying

IDXGInterpace Biosciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Interpace Biosciences

 PRESS RELEASE
Free
IDXG Interpace Biosc...

Interpace Biosciences Announces First Quarter 2025 Financial and Busin...

Interpace Biosciences Announces First Quarter 2025 Financial and Business Results  ●Q1 Revenue of $11.5 million; a 13% increase year-over-year ●Q1 Cash Collections of $11.3 million; a 10% increase year-over-year to record levels ●Q1 Thyroid test volume up 16% year-over-year to record levels ●Q1 Thyroid revenue of $8.0M; up 19% year-over-year to record levels ●Initiates Full Year 2025 Revenue Guidance of approximately $38 million    PARSIPPANY, NJ, May 08, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for...

May 8, 2025 1 EN
 PRESS RELEASE
Free
IDXG Interpace Biosc...

Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Sp...

Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that the Genetic Testing for Oncology (L39365) Local Coverage Determination (LCD) issued by the Medicare Administrative Contractor Novitas Solutions will go into effect, ending reimburs...

April 24, 2025 1 EN
 PRESS RELEASE
Free
IDXG Interpace Biosc...

Interpace Biosciences Announces Preliminary Full-year and Fourth Quart...

Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results  ●Q4 and FY Test volume increase 21% and 17% year-over-year ●Q4 and FY Volume, Revenue, and Profitability at all-time record levels     PARSIPPANY, NJ, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced preliminary financial and business results for the fiscal year and fourth quarter ended December 31, 2024. Fourth quarter Molecular Volume increased 21% year-over-year compared to Q4 2023, and 17% for the Full ...

January 31, 2025 1 EN
 PRESS RELEASE
Free
IDXG Interpace Biosc...

PancraGEN® Will Continue to be Offered While Interpace Re-evaluates it...

PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan PARSIPPANY, NJ, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today announced notification that the Centers for Medicare & Medicaid Services (CMS) directed its Medicare Administrative Contractors, Novitas and First Coast Service Options, Inc., to delay implementation of the Genetic Testing for Oncology Local Coverage Determination (LCD) (L39365), from February 23, 2025, to April 24,...

January 27, 2025 1 EN
 PRESS RELEASE
Free
IDXG Interpace Biosc...

Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer Pancra...

Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk PARSIPPANY, NJ, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today responded to the final Local Coverage Determination (LCD) of Genetic Testing for Oncology (L39365) issued by the Centers for Medicare & Medicaid Services (CMS). The new LCD establishes non-coverage for the Company’s widely used PancraGEN® test. PancraGEN is a DNA-based diagnostic mo...

January 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch